TOBREX OPH OINT Rx
Generic Name and Formulations:
Tobramycin 0.3%; contains chlorobutanol.
Alcon Laboratories, Inc.
Indications for TOBREX OPH OINT:
Susceptible infections of conjunctiva and cornea.
Adults and Children:
<2mos: not established. ≥2mos: Mild to moderate infections: 1–2 drops every 4hrs or ½ inch of ointment 2–3 times daily. Severe infections: 2 drops every hr or ½ inch of ointment every 3–4hrs until improvement; then reduce before discontinuing.
Discontinue if superinfection or hypersensitivity occurs. Remove contact lenses before using. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concomitant systemic aminoglycosides: monitor levels.
Lid itching/swelling, conjunctival erythema, hypersensitivity; oint: may retard corneal healing.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer